# National Cancer Institute

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/national-cancer-institute/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | US research institute, part of National Institutes of Health |
| OpenAlex ID | https://openalex.org/F4320337351 |
| ROR ID | https://ror.org/040gcmg81 |
| Works | 701,605 |

## Funder papers

Showing 15 of 70.

- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial](https://scholariq.org/papers/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial](https://scholariq.org/papers/long-term-primary-results-of-accelerated-partial-breast-irradiation-after-breast/)
- [Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor](https://scholariq.org/papers/heterogeneity-underlies-the-emergence-of-i-egfr-i-t790-wild-type-clones/)
- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study](https://scholariq.org/papers/durvalumab-in-combination-with-olaparib-in-patients-with-relapsed-sclc-results/)
- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Development and Validation of Objective Performance Metrics for Robot-Assisted Radical Prostatectomy: A Pilot Study](https://scholariq.org/papers/development-and-validation-of-objective-performance-metrics-for-robot-assisted/)
- [Financial Burden of Pediatric Cancer for Patients and Their Families](https://scholariq.org/papers/financial-burden-of-pediatric-cancer-for-patients-and-their-families/)
- [Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes](https://scholariq.org/papers/small-cell-lung-cancers-in-patients-who-never-smoked-cigarettes/)
- [Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation](https://scholariq.org/papers/integrative-analysis-of-a-large-real-world-cohort-of-small-cell-lung-cancer-2/)
- [Feasibility and Quit Rates of the Tobacco Status Project: A Facebook Smoking Cessation Intervention for Young Adults](https://scholariq.org/papers/feasibility-and-quit-rates-of-the-tobacco-status-project-a-facebook-smoking/)
- [Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial](https://scholariq.org/papers/efficacy-of-maintenance-olaparib-for-patients-with-newly-diagnosed-advanced/)
- [Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers](https://scholariq.org/papers/molecular-biomarkers-of-disease-outcomes-and-mechanisms-of-acquired-resistance/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.